<DOC>
	<DOCNO>NCT02474316</DOCNO>
	<brief_summary>This prospective , randomize , multicenter , open-label study . After 24 week NA treatment , HBeAg positive CHB patient achieve HBV DNA &lt; 1000copies/ml HBeAb negative , randomize ( 1:1 ) 2 study arm follow : Arm A : Peginterferon alfa-2a 180μg /wk plus NA 1 piece qd 48 week Arm B : Entecavir 0.5mg qd 48 week</brief_summary>
	<brief_title>Combined Therapy With Peginterferon Alfa-2a With NA NA-treated HBeAg Positive Patients</brief_title>
	<detailed_description>This prospective , randomize , multicenter , open-label study . After 24 week NA treatment , HBeAg positive CHB patient achieve HBV DNA &lt; 1000copies/ml HBeAb negative , randomize ( 1:1 ) 2 study arm follow : Arm A : Peginterferon alfa-2a 180μg /wk plus NA 1piece qd 48 week Arm B : NA 1 piece qd 48 week The primary endpoint : HBeAg seroconversion week 48</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age ≥18 ≤65 year ; 2 . There evidence HBsAg HBeAg positive 6 month HBsAb HBeAb negative treat Entecavir ; 3 . Treated NA 24 week achieve HBV DNA &lt; 1000copies/ml HBeAb negative ; 4 . Women without ongoing pregnancy breast feed willing take effective contraceptive measure treatment 5 . Agree participate study sign patient inform consent . 1 . Coinfection active hepatitisA , hepatitisC , hepatitisD and/or human immunodeficiency virus ( HIV ) 2 . AFP &gt; 50ng/ml and/or evidence hepatocellular carcinoma 3 . Evidence decompensated liver disease ( ChildPugh score &gt; 5 ) . ChildPugh &gt; 5 mean , one follow 6 condition meet , patient exclude : 1 . Serum albumin &lt; 35 g/L ; 2 . Prothrombine time prolonged≥ 4 second PTA &lt; 60 % ; 3 . Serum bilirubin &gt; 34 µmol/L ; 4 . History encephalopathy ; 5 . Ascites 4 . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) 5 . Pregnant breastfeed Women 6 . ANC &lt; 1.5x 10^9/L PLT &lt; 90x 10^9/L 7 . Consuming alcohol excess 20g/day woman 30g/day men within 6 month prior enrollment 8 . History severe psychiatric disease , especially depression . Severe psychiatric disease define major depression psychosis treat antidepressant medication major tranquilizer therapeutic dos respectively time prior 3 month history follow : suicidal attempt hospitalization psychiatric disease , period disability due psychiatric disease 9 . History immunologically mediate disease , ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) 10 . History esophageal varix bleed evidence esophageal varix bleed symptom consistent decompensated liver disease 11 . History chronic pulmonary disease associate functional limitation 12 . History severe cardiac disease ( e.g. , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) 13 . Hemodialysis patient patient renal insufficiency 14 . History severe seizure disorder current anticonvulsant use 15 . Major organ transplantation evidence severe illness , malignancy , condition , would make patient , opinion investigator , unsuitable study 16 . History thyroid disease poorly control prescribed medication 17 . Evidence severe retinopathy clinically relevant ophthalmologic disorder 18 . History severe disease evidence severe disease illness condition investigator believe patient suitable join study 19 . Immunomodulatory treatment ( include interferon ) LDT within 1 year prior first dose treatment 20 . Patients include another trial give investigational drug within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>